Table 2.

Results of the EDIM blood test and tumor markers (CEA and CA19-9) in cholangiocellular carcinoma ($n=$ 10), pancreatic carcinoma ($n=$ 34), colorectal carcinoma ($n=$ 18), healthy individuals ($n=$ 16) and patients with inflammation ($n=$ 13)

Patient group	EDIM-Apo10		EDIM-TKTL1		EDIM-Apo10/TKTL1		CEA		CA 19-9
	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive
CCC	1 (10%)	9 (90%)	2 (20%)	8 (80%)	0 (0%)	10 (100%)	7 (77.8%)	2 (22.2%)	3 (30%)	7 (70%)
PC	4 (11.8%)	30 (88.2%)	0 (0%)	34 (100%)	0 (0%)	34 (100%)	20 (63%) 2.5	12 (37.5%)	9 (27.3%)	24 (72.7%)
CRC	2 (11.1%)	16 (88.9%)	1 (5.6%)	17 (94.4%)	0 (0%)	17 (100%)	9 (50%)	9 (50%)	7 (43.8%)	9 (56.3%)
HI	16 (100%)	0 (0%)	16 (100%)	0 (0%)	16 (100%)	0 (0%)	–	–	–	–
INFL	13 (100%)	0 (0%)	11 (85.6%)	2 (15.4%)	12 (92.3%)	1 (7.7%)	–	–	–	–

Abbreviations: CCC, cholangiocellular carcinoma; PAN, pancreas carcinoma; CRC, colorectal carinoma; HI, healthy individuals; INFL, inflammation.